Farmas USA

MACK , premarket a 3,52$ pfff wtf!

MACK

Mi orden a 3,60 que ayer no entró por los pelos igual la voy a ir bajando a 3,33 (aunque sería mucha tela de bajada). Y si no llega pues mejor para los que la lleváis y un susto que me ahorro yo.

Nunca pense que diria esto ...

Zacks upgrade a BUY
https://www.zacks.com/stock/quote/MACK?q=mack

vamosssss! Ja ja

MACK

NVIV

Artículo de SA de ayer sobre la historia y oferta de PixarBio y el CEO:

In November 2013 shortly after Mr. Reynolds departure, InVivo filed a lawsuit against Mr. Reynolds alleging breaches of fiduciary duties, breach of contract, misappropriation of corporate assets, unjust enrichment, corporate waste, and seeking money damages and accounting. Mr. Reynolds filed counterclaims alleging breach of contract, breach of covenant of good faith and fair-dealing, and tortious interference with a contract, and seeking monetary damages.

Reynolds claimed a Director of InVivo, Brian Lugue, told investors that Reynolds "had been forced to resign because the NeuroScaffold clinical studies were 'bogus' and their result had been 'fudged' by Reynolds." Reynolds alleged potential investors have declined to fund PixarBio, "due to allegations concerning mismanagement and misconduct while he was at InVivo."

During the early summer months of 2016, enrollment was going slower than expected and in July investors found out why. The company announced that the 9th and 10th patients had been implanted but at the same time announced a "minor" modification in the study protocol and revealed that the trial had been on hold for a brief period. More importantly, the FDA also recommended that InVivo include a control arm in the study as part of a Study Design Consideration. Prior FDA guidance did not require a control arm but instead compared InVivo's results to historical benchmarks. The goal posts had just been moved!
in October, the Chief Medical Officer resigned from the company, never a good sign for a developmental stage biotech. It was also revealed in October that the FDA had rejected the cervical study pending final results of the INSPIRE study.

http://seekingalpha.com/article/4035317-backdrop-pixarbios-offer-acquire-invivo-therapeutics

PSTI

Creo que será mi corto del pre

Pluristem Therapeutics (PSTI) Phase III study of its PLX-PAD cells Cleared by FDA

Company’s Phase III study of its PLX-PAD cells in the treatment of critical limb ischemia (CLI) was cleared by the U.S. Food and Drug Administration (FDA). Pluristem’s strategy is to use this single multinational Phase III study to support the submission of a biologics license application (BLA) to the FDA for marketing approval. Pluristem expects to begin enrolling patients in its Phase III study in both the U.S. and Europe during the first half of 2017.

http://www.streetinsider.com/Corporate+News/Pluristem+Therapeutics+%28PSTI%29+Phase+III+study+of+its+PLX-PAD+cells+Cleared+by+FDA/12410659.html?si_client=intbro

ITEK

El CEO se ha comprado 60000 cromos a 1,75 dicen por ahí

AMAG

Gran perdedora de la JPM: -30%. ¿Alguien la sigue? Me dan ganas de echarle un largo.

The company released a number of updates today which disappointed investors. It agreed to make an upfront payment of $60m to Palatin Technologies, Inc. for (NYSEMKT:PTN) for rights to Rekynda(bremelanotide) for treatment of hypoactive sexual desire disorder (HSDD). However, the major catalyst was a downgrade by Raymond James from Market Perform to Underperform. Makena, the key revenue earner for the company, only has orphan drug status until February 2018 and today it noted that it has discontinued a recently initiated comparative pain study and it will not plan to request orphan exclusivity as part of an upcoming Supplemental New Drug Application for Makena.

Edito: dentro largo 22,95.

Corto PSTI: 1,55

KITE

Kite Pharma and Fosun Pharma Establish Joint Venture in China to Develop and Commercialize Autologous T-Cell Therapies to Treat Cancer

https://finance.yahoo.com/news/kite-pharma-fosun-pharma-establish-083000654.html